Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NYSE:OGN NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$245.11-0.4%$231.54$150.89▼$250.74$15.30B0.41703,234 shs157,170 shsBBIOBridgeBio Pharma$67.15-0.5%$71.27$31.77▼$84.94$13.15B1.022.72 million shs1.10 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsSMMTSummit Therapeutics$17.27+0.7%$18.52$13.83▼$30.98$13.41B-1.253.23 million shs1.02 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+4.34%+7.31%+11.64%+10.80%+52.56%BBIOBridgeBio Pharma-0.94%-5.15%-6.23%-0.88%+88.28%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%SMMTSummit Therapeutics-3.92%-20.08%-10.77%+14.41%-29.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$245.11-0.4%$231.54$150.89▼$250.74$15.30B0.41703,234 shs157,170 shsBBIOBridgeBio Pharma$67.15-0.5%$71.27$31.77▼$84.94$13.15B1.022.72 million shs1.10 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsSMMTSummit Therapeutics$17.27+0.7%$18.52$13.83▼$30.98$13.41B-1.253.23 million shs1.02 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+4.34%+7.31%+11.64%+10.80%+52.56%BBIOBridgeBio Pharma-0.94%-5.15%-6.23%-0.88%+88.28%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%SMMTSummit Therapeutics-3.92%-20.08%-10.77%+14.41%-29.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.95Moderate Buy$291.3318.86% UpsideBBIOBridgeBio Pharma 2.92Moderate Buy$87.7130.63% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.32% DownsideSMMTSummit Therapeutics 2.50Moderate Buy$27.5859.72% UpsideCurrent Analyst Ratings BreakdownLatest OGN, ASND, BBIO, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ASNDAscendis Pharma A/S Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$330.00 ➝ $326.005/4/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $23.005/1/2026SMMTSummit Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $16.004/29/2026BBIOBridgeBio Pharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$95.00 ➝ $102.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$106.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/21/2026SMMTSummit Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026ASNDAscendis Pharma A/S Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$262.00 ➝ $292.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$720.13M21.23N/AN/A($2.97) per share-82.53BBIOBridgeBio Pharma$502.08M26.19N/AN/A($10.77) per share-6.23OGNOrganon & Co.$6.22B0.56$5.73 per share2.32$3.44 per share3.87SMMTSummit TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M-$4.40N/A23.50N/A-30.85%N/A-19.63%N/ABBIOBridgeBio Pharma-$724.93M-$3.78N/A142.86N/A-144.39%N/A-74.43%N/AOGNOrganon & Co.$187M$0.9314.313.871.243.99%99.95%6.22%N/ASMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/ALatest OGN, ASND, BBIO, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.64 million$194.52 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/A2/12/2026Q4 2025ASNDAscendis Pharma A/S-$0.06-$0.64-$0.58-$0.65$285.35 million$290.38 million2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest OGN, ASND, BBIO, and SMMT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.76BBIOBridgeBio PharmaN/A2.772.68OGNOrganon & Co.9.471.971.23SMMTSummit TherapeuticsN/A7.419.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%OGNOrganon & Co.77.43%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%OGNOrganon & Co.1.62%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.81 million167.94 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableOGN, ASND, BBIO, and SMMT HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Summit Therapeutics Boosted by Analyst3 hours ago | marketbeat.comQ2 Earnings Forecast for SMMT Issued By HC WainwrightMay 7 at 8:16 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Given New $23.00 Price Target at HC WainwrightMay 5 at 3:27 AM | americanbankingnews.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4, 2026 | zacks.comSummit Therapeutics: More Uncertainty Heading Into The ASCO PlenaryMay 4, 2026 | seekingalpha.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4, 2026 | 247wallst.comSummit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 4, 2026 | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMay 4, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)May 3, 2026 | theglobeandmail.comSummit Therapeutics (SMMT) Receives a Rating Update from a Top AnalystMay 3, 2026 | theglobeandmail.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next?May 3, 2026 | americanbankingnews.comSMMT stock plunges on wider Q1 loss, lung cancer clinical trial updateMay 2, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 2, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comSummit Therapeutics Shock Move Hits Nasdaq FuturesMay 1, 2026 | kalkinemedia.comKSummit Therapeutics falls after update on Akeso-partnered lung cancer trialMay 1, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?May 1, 2026 | marketbeat.comSummit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026April 30, 2026 | businesswire.comSummit Therapeutics: It Still Feels Like The Market Got Ahead Of ItselfApril 30, 2026 | seekingalpha.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 30, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGN, ASND, BBIO, and SMMT Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$245.11 -1.03 (-0.42%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$67.15 -0.30 (-0.45%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Organon & Co. NYSE:OGN$13.30 -0.02 (-0.11%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Summit Therapeutics NASDAQ:SMMT$17.27 +0.12 (+0.70%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
